share_log

CRISPR Therapeutics | DEFA14A: Others

CRISPR Therapeutics | DEFA14A: Others

CRISPR Therapeutics | DEFA14A:其他
SEC announcement ·  04/09 16:46
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG, a company listed on the US stock exchange under the ticker CRSP.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). This filing is part of the Schedule 14A, which is a proxy statement required by Section 14(a) of the Securities Exchange Act of 1934. The document indicates that CRISPR Therapeutics is the registrant and there are no other parties filing the proxy statement. The company has confirmed that no filing fee is required for this submission.
CRISPR Therapeutics AG, a company listed on the US stock exchange under the ticker CRSP.US, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC). This filing is part of the Schedule 14A, which is a proxy statement required by Section 14(a) of the Securities Exchange Act of 1934. The document indicates that CRISPR Therapeutics is the registrant and there are no other parties filing the proxy statement. The company has confirmed that no filing fee is required for this submission.
在美国证券交易所上市的股票代码为CRSP.US的公司CRISPR Therapeutics AG已向美国证券交易委员会(SEC)提交了明确的额外材料。该文件是附表14A的一部分,附表14A是1934年《证券交易法》第14(a)条要求的代理声明。该文件表明,CRISPR Therapeutics是注册人,没有其他各方提交委托书。该公司已确认本次提交不需要任何申请费。
在美国证券交易所上市的股票代码为CRSP.US的公司CRISPR Therapeutics AG已向美国证券交易委员会(SEC)提交了明确的额外材料。该文件是附表14A的一部分,附表14A是1934年《证券交易法》第14(a)条要求的代理声明。该文件表明,CRISPR Therapeutics是注册人,没有其他各方提交委托书。该公司已确认本次提交不需要任何申请费。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息